Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Market Intelligence

Set Alert for Market Intelligence

UK Aspirin Prices Double In June

Aspirin led the generics with the fastest-rising UK prices in June, according to the latest figures from WaveData.

Market Intelligence Pricing Strategies

European Industry Backs Biosimilars ‘Scorecards’

Medicines for Europe and IQVIA have partnered to test biosimilar sustainability in 12 European countries by issuing scorecards that measure the contribution of a country’s biosimilar policies to health systems.

Biosimilars Europe

Saudi Insurer Ponders Framework For Saving Billions

Bupa Arabia for Cooperative Insurance believes savings of up to 40% per year could be achieved if Saudi Arabia opted for legislation to drive uptake of generic medicines.

Policy & Regulation Saudi Arabia

Biosimilars Boosted By Australian Initiatives

Australia has reaped the rewards of outreach efforts on biosimilars, according to the country’s GBMA off-patent industry association, with the market share enjoyed by biosimilar medicines rising significantly in the two years since Australia’s government issued a grant for educational activities. In future, the GBMA’s Biosimilar Awareness Week could be used as the model for a global biosimilars campaign backed by the IGBA.

Biosimilars Australia

Exemestane Leads May Rises In UK

Exemestane led the steepest price rises for generics seen in the UK in May. However, concession pricing for the breast cancer drug overestimated the actual prices in the market recorded by WaveData.

Market Intelligence Pricing Strategies

Erythromycin And Paracetamol See April Rises In UK

Erythromycin and paracetamol were among the products with the steepest price rises in the UK in April, as the coronavirus pandemic continued to make its effects felt in the generics market.

Market Intelligence United Kingdom
See All
UsernamePublicRestriction

Register